Raising AMD awareness

Article

Novartis Pharmaceuticals UK Ltd, supported by the Royal National Institute of Blind People (RNIB), has launched "Be AMD Aware", a campaign to raise awareness of the risk factors for and symptoms of age-related macular generation (AMD) among those aged 55 and over in the UK.

Novartis Pharmaceuticals UK Ltd, supported by the Royal National Institute of Blind People (RNIB), has launched "Be AMD Aware", a campaign to raise awareness of the risk factors for and symptoms of age-related macular generation (AMD) among those aged 55 and over in the UK.

The awareness campaign was prompted by survey results that showed that 44% of respondents were completely unaware of the condition. The telephone survey - of 519 UK adults (aged ≥50 years), which was conducted by Harris Interactive between November and December 2008 - also showed that 90% of respondents were unable to identify the symptoms of AMD and 70% were unaware that smoking constituted a significant risk for AMD development.

The "Be AMD Aware" campaign aims to encourage over-55s in the UK to undergo regular eye examinations and to become more aware of AMD symptoms to enable early detection. Information for the general public is available at www.beAMDaware.co.uk.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.